SEC Form 3 · accession 0001140361-16-060472
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
S. Edward Torres
10% Owner
Lilly Ventures Fund I LLC
10% Owner
Armen Shanafelt
Director · 10% Owner
Period of report
Apr 6, 2016
Accepted (ET)
Apr 6, 2016 · 7:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 57,619 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1 | $0.00 | holding | — | — | — | — | — | Common Stock | 890,476 | — | D |
| Series B Preferred StockF1 | $0.00 | holding | — | — | — | — | — | Common Stock | 1,120,448 | — | D |
Explanation of responses
- F1Each share of Series A Preferred Stock and Series B Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.